Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright

Posted by Francis Steltz on May 22nd, 2026

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Free Report) – Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Belite Bio in a note issued to investors on Thursday, May 21st. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of $3.72 per share for the quarter. HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at $0.53 EPS and Q4 2027 earnings at $2.02 EPS.

Belite Bio (NASDAQ:BLTE – Get Free Report) last posted its earnings results on Wednesday, May 20th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26.

Other research analysts have also issued research reports about the company. Needham & Company LLC set a $217.00 target price on Belite Bio in a report on Tuesday, March 3rd. Wall Street Zen raised Belite Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Mizuho set a $223.00 price objective on Belite Bio in a report on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a report on Tuesday, April 7th. Finally, Morgan Stanley boosted their price objective on Belite Bio from $191.00 to $201.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Belite Bio has a consensus rating of “Moderate Buy” and an average target price of $202.33.

Get Our Latest Research Report on BLTE

Belite Bio Stock Up 0.6%

BLTE stock opened at $144.25 on Friday. The firm has a market capitalization of $5.76 billion, a PE ratio of -57.02 and a beta of -1.19. Belite Bio has a twelve month low of $56.10 and a twelve month high of $200.00. The stock has a 50-day simple moving average of $159.99 and a two-hundred day simple moving average of $156.74.

Institutional Trading of Belite Bio

A number of hedge funds have recently bought and sold shares of BLTE. Caitong International Asset Management Co. Ltd lifted its position in Belite Bio by 28,200.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after buying an additional 282 shares during the last quarter. Bank of America Corp DE lifted its position in Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after buying an additional 257 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Belite Bio in the 4th quarter worth approximately $103,000. Persistent Asset Partners Ltd bought a new stake in Belite Bio in the 4th quarter worth approximately $108,000. Finally, EverSource Wealth Advisors LLC bought a new stake in Belite Bio in the 2nd quarter worth approximately $147,000. Institutional investors own 0.53% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Hao-Yuan Chuang sold 6,200 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $181.50, for a total transaction of $1,125,300.00. Following the completion of the transaction, the chief financial officer owned 93,800 shares of the company’s stock, valued at approximately $17,024,700. The trade was a 6.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yu-Hsin Lin sold 9,200 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $181.45, for a total value of $1,669,340.00. Following the transaction, the chief executive officer directly owned 170,934 shares of the company’s stock, valued at $31,015,974.30. The trade was a 5.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 26,166 shares of company stock worth $4,548,351 over the last three months. Company insiders own 13.29% of the company’s stock.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.